Navigation Links
FDA's Office of New Drugs Meets With Cell Therapeutics on its Appeal on Pixantrone
Date:3/3/2011

SEATTLE, March 3, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) today announced that it has met with officials of the FDA's Office of New Drugs ("OND") in Maryland and presented its arguments supporting the Company's belief that the data contained in its New Drug Application ("NDA") 22-481 support the conclusion that pixantrone is effective for its planned use.

"We appreciate OND's consideration of our appeal.  While we understand disputes of this type are a challenging process, we felt compelled to seek this review based on the PIX301 results and lack of approved therapies for these patients with an unmet medical need.  CTI is committed to the advancement of pixantrone," said James A. Bianco, M.D., CEO of CTI.

At the meeting, the OND requested additional analyses from the PIX301 Phase III clinical study.  CTI intends to submit the requested information and expects that this will reset the time period for OND to provide its decision on the appeal.  CTI anticipates a decision in the second quarter of 2011.

About PixantronePixantrone is a novel aza-anthracenedione that has distinct structural and physio-chemical properties that make its anti-tumor activity unique in this class of agents.  Similar to anthracyclines, pixantrone inhibits Topo-isomerase II but unlike anthracyclines--rather than intercalation with DNA--pixantrone alkylates DNA--forming stable DNA adducts, with particular specificity for CpG rich, hyper-methylated sites.  These structural differences resulted in significantly enhanced anti-lymphoma activity compared to doxorubicin in preclinical models.  In addition, the structural motifs on anthracycline-like agents that are responsible for the generation of oxygen free radicals and the formation of toxic drug-metal complexes have also been modified in pixantrone to prevent the binding of iron and perpetuation of superoxide production--both of which are the putative
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. PDL BioPharma Announces European Patent Office Determination of Validity of PDLs European Patent is Final
2. Thomas, McNerney & Partners Expands Team and Moves West Coast Office to San Diego
3. Masters Pharmaceutical, Inc. Appoints Wayne A. Corona to President and Chief Operating Officer
4. ERT Announces the Appointment of Eric Schwartz as Chief Legal Officer
5. Siemens Appoints Overhage as New Chief Medical Informatics Officer
6. Dr. Jeffrey Freitag Appointed Chief Medical Officer of PharmaNet
7. AVANIR Pharmaceuticals Appoints Gregory J. Flesher to Senior Vice President and Chief Business Officer
8. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
9. Baxano, Inc. Names George A. Harter, Jr. as Chief Financial Officer
10. Arena Pharmaceuticals Announces Upcoming Departure of Chief Financial Officer
11. 3-V Biosciences Promotes Stephen R. Brady to Chief Business Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today ... the second quarter ending June 30, 2015. ... organization.  We are excited to be near the completion ... conducted with topline results expected in the fourth quarter," ... Therapeutics, Inc. "Translarna is now commercially available in 12 ...
(Date:7/30/2015)... WOODCLIFF LAKE, N.J. , July 30, 2015 /PRNewswire/ ... submitted simultaneously in the United States ... (to the FDA, EMA and MHLW, respectively) for eribulin, ... sarcoma (STS) who have received prior chemotherapy for advanced ... are based on data from a pivotal global Phase ...
(Date:7/30/2015)... FAIRFIELD, N.J. , July 30, 2015 /PRNewswire/ ... Ferrer, completed the second Phase III clinical study ... development for impetigo.  Medimetriks owns the exclusive U.S. ... The global trial, conducted at 44 centers with ... and pediatric patients aged 2 months and older ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
... 2012 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: ... received written notification on May 25, 2012, from the ... York Stock Exchange LLC ("NYSE"), that the staff had ... of the Company and file a delisting application with ...
... Today the House passed H.R. 5651, its version ... including important provisions to mitigate drug shortages, most notably ... the world,s largest professional society concerned with the causes ... members who specialize in blood cancers such as leukemia, ...
Cached Medicine Technology:American Oriental Bioengineering Inc. Announces Suspension of Trading in its Common Stock and the Initiation of Delisting Proceedings by NYSE 2American Society of Hematology Statement on House Passage of Prescription Drug User Fee Act (PDUFA) 2
(Date:7/30/2015)... California (PRWEB) , ... July 30, 2015 , ... ... services, announced today that the latest issue of Inclusive™ magazine, its multimedia publication ... platforms. The digital edition of the new issue, Volume 6, Issue 2, as ...
(Date:7/30/2015)... ... 2015 , ... Western University of Health Sciences faculty, students and alumni were ... largest sports and humanitarian event in the world this year and the single biggest ... July 25 through August 2, 2015, benefited from the participation of WesternU’s colleges of ...
(Date:7/30/2015)... ... July 30, 2015 , ... On July 23rd ... in taxpayer money to fund the state’s large prison system, which has amassed largely ... highest rates of incarceration. In light of President Obama’s recent reduction of non violent ...
(Date:7/30/2015)... ... July 30, 2015 , ... Quintessa Medical Spa is happy to offer ... treatment designed specifically for the elimination of excess tissue under the chin, referred ... the state of Wisconsin to offer this innovative treatment. , Developed by Kythera Biopharmaceuticals, ...
(Date:7/30/2015)... ... July 30, 2015 , ... Gummy smile surgeon, Dr. Alex ... and surgery, as well as the patented gum depigmentation treatmet. Dr. Farnoosh is a ... with many patients from around the world. , “Like treatment of any other disease ...
Breaking Medicine News(10 mins):Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 2Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 4Health News:WesternU Makes Big Impact at Special Olympics 2Health News:WesternU Makes Big Impact at Special Olympics 3Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 2Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 3Health News:Quintessa MedSpa Offers Nonsurgical Double-chin Elimination 2Health News:Gummy Smile Dentist, Alex Farnoosh DMD, is Now Offering Comprehensive Treatment Options for Gummy Smiles 2
... Center in Philadelphia have found that a signaling protein ... turned on in nearly all recurrent prostate cancers that ... up, the protein, called Stat5, may be a specific ... addition, the researchers, led by Marja Nevalainen, M.D., Ph.D., ...
... and use caution when exiting transportation , , SUNDAY, Dec. 30 ... slush and ice of winter requires special walking tactics, health ... careful, particularly since we haven,t had this type of weather ... specialist at Mount Sinai,s Department of Orthopaedics in New York ...
... injuries can happen to kids if precautions are skipped, ... Winter sports provide kids with great exercise and fun, ... say pediatric trauma experts. , "We see a startling ... snowmobile crashes and beyond," Amy Teddy, manager of the ...
... to make a different kind of New Year,s resolution, ... America,s Blood Centers and blood transfusion recipients across,the country ... National Blood Donor Month., Each year, more than ... to a recent study by W. Riley (et al) ...
... Dec. 28 Grubb & Ellis,Healthcare REIT, Inc. has ... closed on December 21, 2007., Park Place Office ... 133,000 square feet on eight and a half,acres in ... constructed in 1987,1988, and 2002, respectively, and offer tenants ...
... 500 Jobs, HARRISBURG, Pa., Dec. 28 A ... of the Butler,Memorial Hospital that will include a new ... the Department of Community and,Economic Development announced today. The ... The state,s aid will come in the form ...
Cached Medicine News:Health News:Jefferson scientists find protein potential drug target for treatment-resistant prostate cancer 2Health News:Put Safety First During Winter Fun 2Health News:America's Blood Centers Thanks Donors During Celebration of National Blood Donor Month 2Health News:America's Blood Centers Thanks Donors During Celebration of National Blood Donor Month 3Health News:Grubb & Ellis Healthcare REIT Acquires Park Place Office Park in Dayton, Ohio 2Health News:Grubb & Ellis Healthcare REIT Acquires Park Place Office Park in Dayton, Ohio 3Health News:Pennsylvania Invests $13.4 Million to Kick Off Butler Memorial Hospital Expansion 2
Inquire...
... The Eppendorf Reference Series 2000 Pipette ... smooth stroke, a compact and robust design, ... button is used to operate the measuring ... the tip. Product features:Eppendorf "pipette/tip" system ensures ...
... Pipette is a synonym for pipetting accuracy, ... design, and superior operating comfort. Its single, ... measuring stroke and blow-out as well as ... ensures utmost accuracy and precision. Ejection sleeve ...
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
Medicine Products: